|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 50, S423-S428, April 2009
Prostanoids in health and disease
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, PA 19104 This work was supported by grants from the National Institutes of Health (HL-83799, HL-62250, HL-081012, HL-066233, and RR-023567), the American Heart Association (Jon Holden DeHaan Foundation 0730314N, 0430148N, and 0735397N), and the University of Pennsylvania's Institute for Translational Medicine and Therapeutics' Transdisciplinary Program in Translational Medicine and Therapeutics (UL1RR024134). Published, JLR Papers in Press, December 17, 2008.
1 To whom correspondence should be addressed. e-mail: garret{at}exchange.upenn.edu
The prostanoids are a family of lipid mediators generated by the action of cyclooxygenase on a 20-carbon unsaturated fatty acid, arachidonic acid. Prostanoids are generated widely in response to diverse stimuli and, acting in a paracrine or autocrine manner, play important roles in normal physiology and disease. This review summarizes the current knowledge on prostanoid generation and the roles of individual mediators, their biosynthetic pathways, and their receptors in health and disease.
Supplementary key words prostaglandins lipids autacoids Abbreviations: AA, arachidonic acid; AAA, abdominal aortic aneurysm; Ang, angiotensin; COX, cyclooxygenase; IP, I prostanoid; NSAID, nonsteroidal anti-inflammatory drug; PG, prostaglandin; TxA2, thromboxane A2
Related Webpages:
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||